Búsqueda del medicamento por su nombre

Ser-Ap-Es y Lupus eritematoso

Resultado de la verificación de la interacción del medicamento Ser-Ap-Es y la enfermedad de Lupus eritematoso en la seguridad cuando se comparte.

Resultado de la verificación:

Ser-Ap-Es <> Lupus eritematoso

Relevancia: 23.07.2019 Examinador: P.M. Shkutko, M.D., in

Al verificar la interacción según fuentes acreditadas Drugs.com, Rxlist.com, Webmd.com, Medscape.com contraindicaciones o efectos secundarios se han encontrado que pueden causar daño o aumentar el efecto negativo cuando el medicamento se usa con esta enfermedad concomitante.

Consumidor:

El uso de hidralazina ha sido asociada con el desarrollo de lupus eritematoso sistémico y como lupus síndromes, así como la exacerbación de la enfermedad. La hidralazina la terapia debe suspenderse en los pacientes que experimentan un empeoramiento de la preexistente lupus. Monitoreo de conteos sanguíneos completos, y los títulos de anticuerpos antinucleares antes y durante la terapia prolongada se recomienda.

Fuentes

Shapiro KS, Pinn VW, Harrington JT, Levey AS "Immune complex glomerulonephritis in hydralazine-induced SLE." Am J Kidney Dis 3 (1984): 270-4
Pirmohamed M "Hydralazine-induced lupus: yet another autoantibody! triplex-DNA stabilization by hydralazine and the presence of anti-(triplex DNA) antibodies in patients treated with hydralazine - comment." Hum Exp Toxicol 15 (1996): 361-2
Darwaza A, Lamey P-J, Connell JM "Hydrallazine-induced Sjogren's syndrome." Int J Oral Maxillofac Surg 17 (1988): 92-3
Carey RM, Coleman M, Feder A "Pericardial tamponade: a major presenting manifestation of hydralazine-induced lupus syndrome." Am J Med 54 (1973): 84-7
Freestone S, Ramsay LE "Transient monoclonal gammopathy in hydralazine-induced lupus erythematosus." Br Med J 285 (1982): 1536-7
Sturman SG, Kumararatne D, Beevers DG "Fatal hydralazine-induced systemic lupus erythematosus." Lancet 12/03/88 (1988): 1304
Cush JJ, Goldings EA "Southwestern internal medicine conference: drug-induced lupus: clinical spectrum and pathogenesis." Am J Med Sci 290 (1985): 36-45
Weinstein J "Hypocomplementemia in hydralazine-associated systemic lupus erythematosus." Am J Med 65 (1978): 553-6
"Product Information. Apresoline (hydralazine)." Ciba Pharmaceuticals, Summit, NJ.
Innes A, Rennie JA, Cato GR "Drug-induced lupus caused by very-low-dose hydralazine." Br J Rheumatol 25 (1986): 225-31
Ihle BU, Whitworth JA, Dowling JP, Kincaid-Smith P "Hydralazine and lupus nephritis." Clin Nephrol 22 (1984): 230-8
Lunde PK, Frislid K, Hansteen V "Disease and acetylation polymorphism." Clin Pharmacokinet 2 (1977): 182-97
Fleming MG, Bergfeld WF, Tomecki KJ, et al "Bullous systemic lupus erythematosus." Int J Dermatol 28 (1989): 321-6
Blumenkrantz N, Christiansen AH, Ullman S, Asboe-Hansen G "Hydralazine-induced lupoid syndrome." Acta Med Scand 195 (1974): 443-9
Cameron HA, Ramsay LE "The lupus syndrome induced by hydralazine: a common complication with low dose treatment." Br Med J 289 (1984): 410-12
Macleod WN "Anaemia in the hydrallazine-induced lupus syndrome." Scott Med J 28 (1983): 181-2
Ramsey-Goldman R, Franz T, Solano FX, Medsger TA "Hydralazine induced lupus and sweet's syndrome: report and review of the literature." J Rheumatol 17 (1990): 682-4
Naparstek Y, Kopolovic J, Tur-Kaspa R, Rubinger D "Focal glumerulonephritis in the course of hydralazine-induced lupus syndrome." Arthritis Rheum 27 (1984): 822-5
Timbrell JA, Facchini V, Harland SJ, Mansilla-Tinoco R "Hydralazine-induced lupus: is there a toxic metabolic pathway?" Eur J Clin Pharmacol 27 (1984): 555-9
Hahn BH, Sharp GC, Irvin WS, et al "Immune responses to hydralazine and nuclear antigens in hydralazine-induced lupus erythematosus." Ann Intern Med 76 (1972): 365-74
Perry HM "Late toxicity to hydralazine resembling systemic lupus erythematosus or rheumatoid arthritis." Am J Med 54 (1973): 58-72

Ser-Ap-Es

Nombre genérico: hydralazine / hydrochlorothiazide / reserpine

Marca comerciale:

Sinónimos: no

¿Qué es Ser-Ap-Es?

Otro medicamento Eliminar

Ser-Ap-Es <> Lupus eritematoso

Relevancia: 23.07.2019 Examinador: P.M. Shkutko, M.D., in

Consumidor:

El uso de diuréticos tiazídicos se ha informado de que, posiblemente, exacerbar o activar lupus eritematoso sistémico. Los casos reportados han sido generalmente asociado con chlorothiazide y la hidroclorotiazida. La terapia con diuréticos tiazídicos deben ser administrados con precaución en pacientes con antecedentes o riesgo de SLE.

Fuentes

"Product Information. HydroDIURIL (hydrochlorothiazide)." Merck & Co, Inc, West Point, PA.
"Product Information. Metahydrin (trichlormethiazide)." Hoechst Marion-Roussel Inc, Kansas City, MO.
"Product Information. Lozol (indapamide)." Rhone-Poulenc Rorer, Collegeville, PA.
Rich MW, Eckman JM "Can hydrochlorothiazide cause lupus?" J Rheumatol 22 (1995): 1001
Parodi A, Romagnoli M, Rebora A "Subacute cutaneous lupus erythematosus-like eruption caused by hydrochlorothiazide." Photodermatol 6 (1989): 100-2
Reed BR, Huff JC, Jones SK, Orton PW, Lee LA, Norris DA "Subacute cutaneous lupus erythematosus associated with hydrochlorothiazide therapy." Ann Intern Med 103 (1985): 49-51
"Product Information. Thalitone (chlorthalidone)." Monarch Pharmaceuticals Inc, Bristol, TN.
Goodrich AL, Kohn SR "Hydrochlorothiazide-induced lupus erythematosus: a new variant?" J Am Acad Dermatol 28 (1993): 1001-2
Brown CW, Deng JS "Thiazide diuretics induce cutaneous lupus-like adverse reaction." J Toxicol Clin Toxicol 33 (1995): 729-33
"Product Information. Diuril (chlorothiazide)." Merck & Co, Inc, West Point, PA.
"Product Information. Zaroxolyn (metolazone)." Rhone-Poulenc Rorer, Collegeville, PA.
"Product Information. Renese-R (reserpine-polythiazide)." Pfizer US Pharmaceuticals, New York, NY.
"Product Information. Diucardin (hydroflumethiazide)." Wyeth-Ayerst Laboratories, Philadelphia, PA.
"Product Information. Enduron (methyclothiazide)." Abbott Pharmaceutical, Abbott Park, IL.